• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Yearly Archive: 2007

  • ATAC Trial: Anastrozole Still Superior At Over Eight Years’ Follow Up
    • in Oncology
    • — 15 Dec, 2007

    ATAC Trial: Anastrozole Still Superior At Over Eight Years’ Follow Up

    Jack Cuzick
    Jack Cuzick

    JACK CUZICK, Wolfson Institute of Preventive Medicine, London
    New data from the ATAC trial, which is testing anastrozole and tamoxifen in early breast cancer, have demonstrated the continued superiority of the aromatase inhibitor. Among other things, the data
    …
    Read more
    New Drug RAD001 Plus Letrozole In Neoadjuvant Therapy For Breast Cancer
    • in Oncology
    • — 15 Dec, 2007

    New Drug RAD001 Plus Letrozole In Neoadjuvant Therapy For Breast Cancer

    Jose Baselga
    Jose Baselga

    JOSE BASELGA, Vall d’Hebron Hospital, Barcelona
    RAD001, a drug targeted at the mTor pathway, has been combined with letrozole in a randomised phase II trial in breast cancer. The investigators saw more responses in the experimental arm, and
    …
    Read more
  • AACR In New Partnership For San Antonio Breast Cancer Symposium
    • in News
    • — 14 Dec, 2007

    AACR In New Partnership For San Antonio Breast Cancer Symposium

    Margaret Foti
    Margaret Foti

    MARGARET FOTI, American Association for Cancer Research, Philadelphia
    The San Antonio Breast Cancer Symposium will, in the future, be presented jointly by the Cancer Therapy and Research Center at the University of Texas Health Science Center, Baylor College
    …
    Read more
    Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide
    • in Oncology
    • — 14 Dec, 2007

    Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide

    Stephen Jones
    Stephen Jones

    STEPHEN JONES, US Oncology Research, Houston
    Long term data from an early breast cancer trial involving cyclophosphamide combined with docetaxel or doxorubicin have shown a survival advantage for the taxane. As Stephen Jones of US Oncology Research explained
    …
    Read more
    • in Oncology
    • — 11 Dec, 2007

    Live Report from ASH:
    Ibritumomab Provides Benefit in Patients with Follicular Lymphoma

    Anton Hagenbeek
    Anton Hagenbeek

    ANTON HAGENBEEK, University Medical Centre Utrecht
    For patients with advanced-stage follicular non-Hodgkin’s lymphoma, ibritumomab tiuxetan seems to prolong progression free survival by two years with favourable toxicity. Sarah Maxwell spoke to study author Anton Hagenbeek at the ASH
    …
    Read more
    • in Oncology
    • — 11 Dec, 2007

    Live Report from ASH:
    Can Intensive Immunochemotherapy Cure Mantle Cell Lymphoma?

    Christian Geisler
    Christian Geisler

    CHRISTIAN GEISLER, Rigshospitalet, Copenhagen
    Mantle cell lymphoma, which was previously considered incurable, has apparently been cured in some patients on a phase II study. Derek Thorne got the details on the study – which featured an intensive immunochemotherapy
    …
    Read more
    • in Oncology
    • — 10 Dec, 2007

    Live Report from ASH:
    Oblimersen Extends Survival in Chronic Lymphocytic Leukemia

    Susan O’Brien
    Susan O’Brien

    SUSAN O’BRIEN, MD Anderson Cancer Center, Houston
    For patients with relapsed or refractory CLL, oblimersen extends survival when added to standard fludarabine/cyclophosphamide chemotherapy. Susan O’Brien presented data from this phase III trial to the American Society of Hematology
    …
    Read more
    • in Oncology
    • — 10 Dec, 2007

    Live Report from ASH:
    Dasatinib Effective At Two Years’ Follow Up in Chronic Phase CML

    Richard Stone
    Richard Stone

    RICHARD STONE, Dana-Farber Cancer Institute, Boston
    GEORGE CANELLOS, Dana-Farber Cancer Institute

    New data shows that dasatinib is giving durable responses in patients with chronic phase chronic myeloid leukemia who have failed, or who cannot tolerate imatinib. So where
    …
    Read more
  • Live Report from ASH: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes
    • in Oncology
    • — 10 Dec, 2007

    Live Report from ASH: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes

    Pierre Fenaux
    Pierre Fenaux

    PIERRE FENAUX, Paris 13 University
    Results from a phase III study presented at ASH suggest that the hypomethylating agent azacitidine should be the new standard of care for patients with high-risk MDS. Pierre Fenaux of Paris 13 University
    …
    Read more
    • in Oncology
    • — 10 Dec, 2007

    Live Report from ASH:
    Interleukin-2 For Acute Myeloid Leukemia In First Remission?

    Jonathan Kolitz
    Jonathan Kolitz

    JONATHAN KOLITZ, Monter Cancer Center, Lake Success, NY
    GEORGE CANELLOS, Dana-Farber Cancer Institute

    For patients with acute myeloid leukemia in first remission, new data suggests that there may be a benefit from interleukin-2. Derek Thorne got the interim
    …
    Read more
  • New Drug AMG 531 Effective in Splenectomized Patients with Chronic Immune Thrombocytopenic Purpura
    • in General Medicine
    • — 9 Dec, 2007

    New Drug AMG 531 Effective in Splenectomized Patients with Chronic Immune Thrombocytopenic Purpura

    Terry Gernsheimer
    Terry Gernsheimer

    TERRY GERNSHEIMER, University of Washington Medical Center, Seattle
    An investigational drug AMG 531 has increased and sustained platelet counts in splenectomized patients with chronic immune thrombocytopenic purpura or ITP. This was in a placebo controlled phase III trial
    …
    Read more
    No Use Of Hydroxyurea In Country With Most Sickle Cell Anemia
    • in Public Health
    • — 9 Dec, 2007

    No Use Of Hydroxyurea In Country With Most Sickle Cell Anemia

    Zakari Aliyu
    Zakari Aliyu

    REFERENCE: American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta
    ZAKARI ALIYU, Howard University, Washington DC
    Nigeria has the highest incidence of sickle cell anemia in the world, with over 150,000 children being born each year with
    …
    Read more
  • Next Page »
  • Sign up for AudioMedica.com news

    * = required field
    Speciality




  • Home
  • 2007

© Copyright 2022 AudioMedica.com. Typegrid Theme by WPBandit.